PHARMING GROUP NV (PHGN.DE) Stock Fundamental Analysis

FRA:PHGN • NL0010391025

1.414 EUR
+0.01 (+0.86%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PHGN. PHGN was compared to 78 industry peers in the Biotechnology industry. PHGN has an average financial health and profitability rating. PHGN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • PHGN had negative earnings in the past year.
  • In the past year PHGN had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHGN reported negative net income in multiple years.
  • In multiple years PHGN reported negative operating cash flow during the last 5 years.
PHGN.DE Yearly Net Income VS EBIT VS OCF VS FCFPHGN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • PHGN has a Return On Assets of 0.08%. This is in the better half of the industry: PHGN outperforms 71.79% of its industry peers.
  • PHGN has a Return On Equity of 0.14%. This is in the better half of the industry: PHGN outperforms 75.64% of its industry peers.
  • The Return On Invested Capital of PHGN (6.65%) is better than 85.90% of its industry peers.
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROIC 6.65%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
PHGN.DE Yearly ROA, ROE, ROICPHGN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • PHGN's Profit Margin of 0.11% is fine compared to the rest of the industry. PHGN outperforms 73.08% of its industry peers.
  • PHGN has a Operating Margin of 10.06%. This is amongst the best in the industry. PHGN outperforms 83.33% of its industry peers.
  • With an excellent Gross Margin value of 89.90%, PHGN belongs to the best of the industry, outperforming 85.90% of the companies in the same industry.
  • PHGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
PHGN.DE Yearly Profit, Operating, Gross MarginsPHGN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • PHGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • PHGN has more shares outstanding than it did 1 year ago.
  • PHGN has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PHGN has an improved debt to assets ratio.
PHGN.DE Yearly Shares OutstandingPHGN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
PHGN.DE Yearly Total Debt VS Total AssetsPHGN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • PHGN has an Altman-Z score of 1.09. This is a bad value and indicates that PHGN is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.09, PHGN is in the better half of the industry, outperforming 60.26% of the companies in the same industry.
  • PHGN has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as PHGN would need 2.49 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.49, PHGN belongs to the best of the industry, outperforming 84.62% of the companies in the same industry.
  • PHGN has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of PHGN (0.46) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Altman-Z 1.09
ROIC/WACC1.2
WACC5.52%
PHGN.DE Yearly LT Debt VS Equity VS FCFPHGN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 3.16 indicates that PHGN has no problem at all paying its short term obligations.
  • PHGN has a Current ratio of 3.16. This is in the better half of the industry: PHGN outperforms 64.10% of its industry peers.
  • PHGN has a Quick Ratio of 2.39. This indicates that PHGN is financially healthy and has no problem in meeting its short term obligations.
  • PHGN has a Quick ratio (2.39) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 2.39
PHGN.DE Yearly Current Assets VS Current LiabilitesPHGN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • PHGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
  • PHGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.78%.
  • The Revenue has been growing by 10.64% on average over the past years. This is quite good.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%

3.2 Future

  • Based on estimates for the next years, PHGN will show a very strong growth in Earnings Per Share. The EPS will grow by 53.15% on average per year.
  • PHGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.63% yearly.
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.15%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y10.63%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHGN.DE Yearly Revenue VS EstimatesPHGN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHGN.DE Yearly EPS VS EstimatesPHGN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Forward Earnings ratio of 63.52, PHGN can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, PHGN is valued a bit cheaper than 74.36% of the companies in the same industry.
  • PHGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE N/A
Fwd PE 63.52
PHGN.DE Price Earnings VS Forward Price EarningsPHGN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 98.72% of the companies in the same industry are more expensive than PHGN, based on the Enterprise Value to EBITDA ratio.
  • 100.00% of the companies in the same industry are more expensive than PHGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.2
EV/EBITDA 0.88
PHGN.DE Per share dataPHGN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • PHGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PHGN's earnings are expected to grow with 65.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.83%
EPS Next 3Y65.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PHGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMING GROUP NV

FRA:PHGN (2/20/2026, 7:00:00 PM)

1.414

+0.01 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners21.51%
Inst Owner ChangeN/A
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap98.51M
Revenue(TTM)362.27M
Net Income(TTM)383.00K
Analysts88.57
Price Target2.18 (54.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.6%
PT rev (3m)N/A
EPS NQ rev (1m)40.1%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-91.51%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)3.45%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 63.52
P/S 0.32
P/FCF 2.2
P/OCF 2.18
P/B 0.44
P/tB 0.89
EV/EBITDA 0.88
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY1.57%
FCF(TTM)0.64
FCFY45.41%
OCF(TTM)0.65
OCFY45.95%
SpS4.42
BVpS3.23
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROCE 9.44%
ROIC 6.65%
ROICexc 11.67%
ROICexgc 30.25%
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
FCFM 14.51%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Debt/EBITDA 2.33
Cap/Depr 4%
Cap/Sales 0.17%
Interest Coverage 5.94
Cash Conversion 102.18%
Profit Quality 13727.2%
Current Ratio 3.16
Quick Ratio 2.39
Altman-Z 1.09
F-Score7
WACC5.52%
ROIC/WACC1.2
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.15%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y10.63%
EBIT growth 1Y355.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year401.72%
EBIT Next 3Y93.29%
EBIT Next 5Y78.86%
FCF growth 1Y309.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325.01%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMING GROUP NV / PHGN.DE FAQ

What is the fundamental rating for PHGN stock?

ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE.


Can you provide the valuation status for PHARMING GROUP NV?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHGN.DE). This can be considered as Fairly Valued.


What is the profitability of PHGN stock?

PHARMING GROUP NV (PHGN.DE) has a profitability rating of 5 / 10.


What is the earnings growth outlook for PHARMING GROUP NV?

The Earnings per Share (EPS) of PHARMING GROUP NV (PHGN.DE) is expected to grow by 111.44% in the next year.